A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Single and Multiple Dose Escalation Study in Healthy Volunteers and an Expansion Cohort in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302
Latest Information Update: 01 Dec 2025
At a glance
- Drugs SPG 302 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Spinogenix
Most Recent Events
- 04 Nov 2025 According to a Spinogenix media release, topline results from the trial presented as a poster at the recent Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Annual Meeting.
- 04 Nov 2025 Results published in the Media Release
- 29 Jun 2025 Status changed from active, no longer recruiting to completed.